Marc Dufour

Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells.

Yvan de Launoit, Raymonde Veilleux, Marc Dufour et al. · PubMed · 1991 · 91 citations · Full text

Medicine, Endocrinology, Pharmacology +15

Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

Didier Roulin, Laurent Waselle, Anne Dormond-Meuwly et al. · Molecular Cancer · 2011 · 70 citations · Full text

Medicine, Oncology, Pharmacology +16

Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells.

Yvan de Launoit, Sophie Dauvois, Marc Dufour et al. · PubMed · 1991 · 59 citations

Medicine, Endocrinology, Pharmacology +12

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives

Marc Dufour, Anne Dormond-Meuwly, Nicolas Demartines et al. · Cancers · 2011 · 53 citations · Full text

Medicine, Oncology, Pharmacology +16

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

Benjamin Blaser, Laurent Waselle, Anne Dormond-Meuwly et al. · BMC Cancer · 2012 · 45 citations · Full text

Medicine, Oncology, Pharmacology +13